Chronic kidney disease, diabetes mellitus and cardiovascular disease: Risks and commonalities

Journal of Renal Care

Volumn 38, Issue SUPPL. 1, 2012, Pages 4-11

  Suckling, Rebecca ^a   Gallagher, Hugh ^a  

^a ST HELIER HOSPITAL   (United Kingdom)

Author keywords

Cardiovascular disease; Chronic kidney disease; Diabetes mellitus; Epidemiology

Indexed keywords

ARTICLE; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY FAILURE; DIABETES MELLITUS; DIABETIC NEPHROPATHY; HUMAN; PREVALENCE; RISK FACTOR;

CARDIOVASCULAR DISEASES; DIABETES COMPLICATIONS; DIABETES MELLITUS; DIABETIC NEPHROPATHIES; HUMANS; PREVALENCE; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS;

EID: 84856927250     PISSN: 17556678     EISSN: 17556686     Source Type: Journal    
DOI: 10.1111/j.1755-6686.2012.00274.x     Document Type: Article

References (67)

1. Adler, A., Stratton, I., Neil H. et al (2000). Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. British Medical Journal 321, 412-419.
2. American Diabetes Association.(2003). Treatment of hypertension in adults with diabetes. Diabetes Care 26, s80-s82.
3. Ansell, D., Feehally, J., Fogarty, D. et al (2010). UK Renal Registry 2009:12th Annual Report of the Renal Association. Nephron Clinical Practice 115(Suppl 1):(I-XIV).
4. Artaza, J., Mehrotra, R. & Norris K. (2009). Vitamin D and the cardiovascular system. Clinical Journal of the American Society of Nephrology 4, 1515-1522.
5. Australian Institute of Health and Welfare. (2009). Prevention of cardiovascular disease, diabetes and chronic kidney disease: targeting risk factors. Cat. no. PHE 118. Canberra : AIHW.
6. Baigent, C., Landray, M.J., Reith C. et al (2011). The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. The Lancet 377, 2181-2192.
7. Block, G., Klassen, P., Lazarus J. et al (2004). Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. Journal of American Society of Nephrology 15, 2208-2218.
8. Bosman, D., Winkler, A., Marsden J. et al (2001). Anaemia with ery-thropoietin deficiency occurs early in diabetic nephropathy. Diabetes Care 24, 495-499.
9. Brenner, B., Cooper, M., de Zeeuw D. et al (2001). Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. The New England Journal of Medicine 345, 861-869.
10. Camargo, E., Soares, A., Detanico A. et al (2011). The Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation is less accurate in patients with Type 2 diabetes when compared with healthy individuals. Diabetic Medicine 28, 90-95.
11. Cheng, C., Chan, J., Cembrowski G. et al (2004). Complete blood count reference interval diagrams derived from NHANES III: stratification by age, sex and race. Laboratory Hematology 10, 42-52.
12. Chronic Kidney Disease Prognosis Consortium. (2010). Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. The Lancet 375, 2073-2081.
13. Coresh, J., Astor, B., Greene T. et al (2003). Prevalence of chronic kidney disease and decreased kidney function in the adult US popu-lation: Third National Health and Nutrition Examination Survey. American Journal of Kidney Diseases 41, 1-12.
14. DCCT/EDIC Study Research Group. (2005). Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. The New England Journal of Medicine 353, 2643-2653.
15. De Nicola, L., Minutolo, R., Zamboli P. et al (2005). Italian audit on therapy of hypertension in chronic kidney disease: the TABLE-CKD study. Seminars in Nephrology 25, 425-430.
16. DeFronzo, R.A. (1981). The effect of insulin on renal sodium metabolism. A review with clinical implications. Diabetologia 21, 165-171.
17. Department of Health. (2006). Quality and Outcomes Framework: Chronic Kidney Disease. London : HMSO.
18. Di Angelantonio, E., Chowdhury, R., Sarwar N. et al (2010). Chronic kidney disease and risk of major cardiovascular disease and non vascular mortality: prospective population based cohort study. British Medical Journal 341, c3986.
19. Foley, R., Murray, A., Shuling L. et al (2005). Chronic kidney disease and the risk for cardiovascular disease, renal replacement and death in the United States Medicare Population, 1998 to 1999. Journal of American Society of Nephrology 15, 489-495.
20. Fried, L., Shlipak, M., Crump C. et al (2003). Renal insufficiency as a predictor of cardiovascular outcomes and mortality in elderly individuals. Journal of American College of Cardiology 41, 1364-1372.
21. Gaede, P., Vedel, P., Larsen N. et al (2003). Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. The New England Journal of Medicine 348, 383-393.
22. Glassock R. & Winearls C. (2010). Diagnosing chronic kidney disease. Current Opinion in Nephrology and Hypertension 19, 123-128.
23. Go, A., Chertow, G., Fan D. et al (2004). Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. The New England Journal of Medicine 351, 1296-1305.
24. Gomez, G., de Lusignan, S. & Gallagher H. (2006). Chronic Kidney Disease: a new priority for primary care. British Journal of General Practice 56, 908-910.
25. Grundy, S., Benjamin, I., Burke G. et al (1999). Diabetes and cardiovascular disease. A statement for healthcare professionals from the American Heart Association. Circulation 100, 1134-1146.
26. Halbesma, N., Kuiken, D.-S., Brantsma A.H. et al (2006). Macroalbuminuria is a better risk marker than low estimated GFR to identify individuals at risk for accelerated GFR loss in population screening. Journal of the American Society of Nephrology 17, 2582-2590.
27. Hallan, S., Coresh, J., Astor B. et al (2006a). International comparison of the relationship of chronic kidney disease prevalence and ESRD risk. Journal of American Society of Nephrology 17, 2275-2284.
28. Hallan, S., Dahl, K., Oien C. et al (2006b). Screening strategies for chronic kidney disease in the general population: follow-up of cross sectional health survey. British Medical Journal 333, 1047.
29. Hallan S. & Orth S. (2010). The KDOQI 2002 classification of chronic kidney disease: for whom the bell tolls. Nephrology Dialysis Transplantation 25, 2832-2836.
30. Hillege, H.L., Fidler, V., Diercks G.F.H. et al (2002). Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 106, 1777-1782.
31. Joint Specialty Committee on Renal Medicine of the Royal College of Physicians and the Renal Association, and the Royal College of General Practitioners. (2006). Chronic Kidney Disease in Adults: UK Guidelines for Identification, Management and Referral. London : Royal College of Physicians.
32. Kannel W.B. & McGee D.L. (1979). Diabetes and cardiovascular risk factors: the Framingham Study. Circulation 59, 8-13.
33. Keane, W., Brenner, B., De Zeeuw, D. et al (2003). The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: The RENAAL Study. Kidney International 63, 1499-1507.
34. King, H., Aubert, R. & Herman W. (1998). Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 21, 1414-1431.
35. Klausen, K., Borch-Johnsen, K., Feldt-Rasmussen B. et al (2004). Very low levels of microalbuminuria are associated with increased risk of coronary heart disease and death independently of renal function, hypertension, and diabetes. Circulation 110, 32-35.
36. Krämer B.K. & Schweda F. (1997). Ramipril in non-diabetic renal failure (REIN study). The Lancet 350, 736-7.
37. Lee, M., Saver, J., Chang K. et al (2010). Low glomerular filtration rate and risk of stroke: meta-analysis. British Medical Journal 341, c4249.
38. Levey A.S., Stevens, L.A., Schmid C.H. et al (2009). A new equation to estimate glomerular filtration rate. Annals of Internal Medicine 150, 604-612.
39. Lewis, E., Hunsicker, L., Bain R. et al (1993). The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy: the Collaborative Study Group. The New England Journal of Medicine 329, 1456-1462.
40. Lewis, E., Hunsicker, L., Clarke W. et al (2001). Renoprotective effect of the angiotensin-receptor antagonist Irbesartan in patients with nephropathy due to type 2 diabetes. The New England Journal of Medicine 345, 851-860.
41. Manjunath G., Tighiouart H., Ibrahim H. et al (2003). Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community. Journal of American College of Cardiology 41, 47-55.
42. Martins, D., Wolf M, Pan D. et al (2007). Prevalence of cardiovascular risk factors and the serum levels of 25-hydroxyvitamin D in the United States: data from the Third National Health and Nutrition Examination Survey. Archives of Internal Medicine 167, 1159-1165.
43. Matsushita, K., Selvin, E., Bash L. et al (2010). Risk implications of the new CKD Epidemiology Collaboration (CKD-EPI) equation compared with the MDRD study equation for estimated GFR: The Atherosclerosis Risk in Communities (ARIC) Study. American journal of kidney diseases 55(4), 648-659 [Epub 2010 Feb 26.
44. Mehdi U. & Toto R. (2008). Anemia, diabetes, and chronic kidney disease. Diabetes Care 32, 1320-1326.
45. Narva, A. (2008). Reducing the burden of chronic kidney disease among American Indians. Advances in Chronic Kidney Disease 15, 168-173.
46. National Collaborating Centre for Chronic Conditions. (2008). Chronic kidney disease: national clinical guideline for early identification and management in adults in primary and secondary care. London : Royal College of Physicians.
47. National Institute for Health and Clinical Excellence. (2008). CG73 Chronic Kidney Disease: NICE Guideline. London : HMSO.
48. O'Hare, J., Ferriss, J., Brady D. et al (1985). Exchangeable sodium and renin in hypertensive diabetic patients with and without nephropathy. Hypertension 7(Suppl II), II43-II48.
49. OÂ'Hare, A.M., Bertenthal, D., Covinsky K.E. et al (2006). Mortality risk stratification in chronic kidney disease: one size for all ages? Journal of the American Society of Nephrology 17, 846-853.
50. Pilz, S., Tomaschitz, A., Friedl C. et al (2011). Vitamin D status and mortality in chronic kidney disease. Nephrology Dialysis Transplantation 26, 3603-3609.
51. Price, D.A., De'Oliveira, J.M., Fisher N.D. et al (1999). The state and responsiveness of the renin-angiotensin-aldosterone system in patients with type II diabetes mellitus. American Journal of Hypertension 12, 348-355.
52. Pyorala, K., Pedersen, T., Kjekshus K. et al (1997). Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease: A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 20, 614-620.
53. Rodriguez, J., Cleries, M. & Vela E. (1997). Diabetic patients on renal replacement therapy: analysis of Catalan Registry data. Renal Registry Committee. Nephrology Dialysis Transplantation 12, 2501-2509.
54. Safar, M.E., London, G.M. & Plante G.E. (2004). Arterial stiffness and kidney function. Hypertension 43, 163-168.
55. Sarafidis, P., Li, S., Chen S. et al (2008). Hypertension awareness, treatment, and control in chronic kidney disease. American Journal of Medicine 121, 322-340.
56. Sowers J.R. & Epstein M. (1995). Diabetes mellitus and associated hypertension, vascular disease, and nephropathy: an update. Hypertension 26, 869-879.
57. Stevens, L., Cooper, S., Singh R. et al (2005). Detection of chronic kidney disease in non-nephrology practices: an important focus for intervention. BC Medical Journal 47, 305-311.
58. Stevens, P., O'Donoghue, D., de Lusignan S. et al (2007). Chronic kidney disease management in the United Kingdom: NEOERICA project results. Kidney International 72, 92-99.
59. Suckling, R., He, F. & MacGregor G. (2010). Altered dietary salt intake for preventing and treating diabetic kidney disease. Cochrane Database of Systematic Reviews. 12: CD006763.
60. The NHS Information Centre. (2011). Quality and Outcome Framework Achievement Data 2009/10.
61. United Kingdom Prospective Diabetes Study Group. (1998). Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352, 837-853.
62. Van Dijk, P., Jager, K., Stengel B. et al (2005). Renal replacement therapy for diabetic end-stage renal disease: data from 10 registries in Europe (1991-2000). Kidney International 67, 1489-1499.
63. Vasavada N. & Agarwal, R. (2003). Role of excess volume in the pathophysiology of hypertension in chronic kidney disease. Kidney International 64, 1772-1779.
64. Wang, T.J., Pencina, M.J., Booth S.L. et al (2008). Vitamin D deficiency and risk of cardiovascular disease. Circulation 117, 503-511.
65. Whaley-Connell, A., Sowers, J., McFarlane S. et al (2008). Diabetes mellitus in CKD: Kidney Early Evaluation Program (KEEP) and National Health and Nutrision and Examination Survey (NHANES) 1999-2004. American Journal of Kidney Disease 52, S21-S29.
66. White, S., Polinghorne, K., Atkins R. et al (2010). Comparison of the prevalence and mortality risk of CKD in Australia using the CKD Epidemiology Collaboration (CKD-EPI) and Modificaiton of Diet in Renal Disease (MDRD) Study GFR estimating equations: the AusDiab (Australian Diabetes, Obesity and Lifestyle) Study. American Journal of Kidney Diseases 55, 660-670.
67. Wild, S., Roglic, G., Green A. et al (2004). Global prevalence of diabetes; estimates for the year 2000 and projections for 2030. Diabetes Care 27, 1047-1053.